Identification of a bilirubin receptor may mediate a component of cholestatic itch

Abstract

Various pathologic conditions result in jaundice, a yellowing of the skin due to a buildup of bilirubin. Patients with jaundice commonly report experiencing an intense non-histaminergic itch. Despite this association, the pruritogenic capacity of bilirubin itself has not been explored, and no bilirubin receptor has been identified. Here, we demonstrate that pathophysiologic levels of bilirubin excite peripheral itch sensory neurons and elicit pruritus through MRGPRs, a family of G-protein coupled receptors expressed in primary sensory neurons. Bilirubin binds and activates two MRGPRs, mouse MRGPRA1 and human MRGPRX4. In two mouse models of pathologic hyperbilirubinemia, we show that genetic deletion of either Mrgpra1 or Blvra, the gene that encodes the bilirubin-producing enzyme, attenuates itch. Similarly, plasma isolated from hyperbilirubinemic patients evoked itch in wild-type animals but not Mrgpra1-/- animals. Removing bilirubin decreased the pruritogenic capacity of patient plasma. Based on these data, targeting MRGPRs is a promising strategy for alleviating jaundice-associated itch.

Data availability

All data generated or analyzed during this study are included in the manuscript. Source data for main figures 1-7 have been provided.

Article and author information

Author details

  1. James Meixiong

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    James Meixiong, is a consultant for Escient Pharmaceuticals a company focused on developing small molecule inhibitors for MRGPRs.
  2. Chirag Vasavda

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  3. Dustin Green

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Qin Zheng

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  5. Lijun Qi

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  6. Shawn G Kwatra

    Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. James P Hamilton

    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  8. Solomon H Snyder

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    For correspondence
    ssnyder1@jhmi.edu
    Competing interests
    No competing interests declared.
  9. Xinzhong Dong

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    For correspondence
    xdong2@jhmi.edu
    Competing interests
    Xinzhong Dong, has a financial interest in Escient Pharmaceuticals a company focused on developing small molecule inhibitors for MRGPRs.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9750-7718

Funding

National Institute of Neurological Disorders and Stroke (R01NS054791)

  • Xinzhong Dong

Howard Hughes Medical Institute

  • Xinzhong Dong

National Institute of Mental Health (MH18501)

  • Solomon H Snyder

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were performed in accordance with protocols approved by the Animal Care and Use Committee at the Johns Hopkins University School of Medicine. All animals were handled according to approved institutional animal care and use committee (IACUC) protocols (MO16M40) of Johns Hopkins University.

Copyright

© 2019, Meixiong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 15,845
    views
  • 895
    downloads
  • 89
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. James Meixiong
  2. Chirag Vasavda
  3. Dustin Green
  4. Qin Zheng
  5. Lijun Qi
  6. Shawn G Kwatra
  7. James P Hamilton
  8. Solomon H Snyder
  9. Xinzhong Dong
(2019)
Identification of a bilirubin receptor may mediate a component of cholestatic itch
eLife 8:e44116.
https://doi.org/10.7554/eLife.44116

Share this article

https://doi.org/10.7554/eLife.44116

Further reading

    1. Cell Biology
    2. Neuroscience
    Jun Sun, Francisca Rojo-Cortes ... Alicia Hidalgo
    Research Article

    Experience shapes the brain as neural circuits can be modified by neural stimulation or the lack of it. The molecular mechanisms underlying structural circuit plasticity and how plasticity modifies behaviour are poorly understood. Subjective experience requires dopamine, a neuromodulator that assigns a value to stimuli, and it also controls behaviour, including locomotion, learning, and memory. In Drosophila, Toll receptors are ideally placed to translate experience into structural brain change. Toll-6 is expressed in dopaminergic neurons (DANs), raising the intriguing possibility that Toll-6 could regulate structural plasticity in dopaminergic circuits. Drosophila neurotrophin-2 (DNT-2) is the ligand for Toll-6 and Kek-6, but whether it is required for circuit structural plasticity was unknown. Here, we show that DNT-2-expressing neurons connect with DANs, and they modulate each other. Loss of function for DNT-2 or its receptors Toll-6 and kinase-less Trk-like kek-6 caused DAN and synapse loss, impaired dendrite growth and connectivity, decreased synaptic sites, and caused locomotion deficits. In contrast, over-expressed DNT-2 increased DAN cell number, dendrite complexity, and promoted synaptogenesis. Neuronal activity modified DNT-2, increased synaptogenesis in DNT-2-positive neurons and DANs, and over-expression of DNT-2 did too. Altering the levels of DNT-2 or Toll-6 also modified dopamine-dependent behaviours, including locomotion and long-term memory. To conclude, a feedback loop involving dopamine and DNT-2 highlighted the circuits engaged, and DNT-2 with Toll-6 and Kek-6 induced structural plasticity in this circuit modifying brain function and behaviour.

    1. Neuroscience
    Mengqiao Cui, Xiaoyuan Pan ... Jun-Li Cao
    Research Article

    Memory impairment in chronic pain patients is substantial and common, and few therapeutic strategies are available. Chronic pain-related memory impairment has susceptible and unsusceptible features. Therefore, exploring the underlying mechanisms of its vulnerability is essential for developing effective treatments. Here, combining two spatial memory tests (Y-maze test and Morris water maze), we segregated chronic pain mice into memory impairment-susceptible and -unsusceptible subpopulations in a chronic neuropathic pain model induced by chronic constrictive injury of the sciatic nerve. RNA-Seq analysis and gain/loss-of-function study revealed that S1P/S1PR1 signaling is a determinant for vulnerability to chronic pain-related memory impairment. Knockdown of the S1PR1 in the dentate gyrus (DG) promoted a susceptible phenotype and led to structural plasticity changes of reduced excitatory synapse formation and abnormal spine morphology as observed in susceptible mice, while overexpression of the S1PR1 and pharmacological administration of S1PR1 agonist in the DG promoted an unsusceptible phenotype and prevented the occurrence of memory impairment, and rescued the morphological abnormality. Finally, the Gene Ontology (GO) enrichment analysis and biochemical evidence indicated that downregulation of S1PR1 in susceptible mice may impair DG structural plasticity via interaction with actin cytoskeleton rearrangement-related signaling pathways including Itga2 and its downstream Rac1/Cdc42 signaling and Arp2/3 cascade. These results reveal a novel mechanism and provide a promising preventive and therapeutic molecular target for vulnerability to chronic pain-related memory impairment.